Abstract
Over the past several years, our group has provided considerable evidence that the expression of sigma-2 (σ2) receptors may serve as a biomarker of tumour cell proliferation. In these in vitro studies, σ2receptors were expressed 8–10 times more in proliferative (P) tumour cells than in quiescent (Q) tumour cells, and the extent and kinetics of their expression were independent of a number of biological, physiological and environmental factors often found in solid tumours. Moreover, the expression of σ2receptors followed both the population growth kinetics when Q-cells were recruited into the P-cell compartment and the proliferative status of human breast tumour cells treated with cytostatic concentrations of tamoxifen. However, these in vitro studies may or may not be indicative of what might occur in solid tumours. In the present study, the σ2receptor P:Q ratio was determined for the cells from subcutaneous 66 (diploid) and 67 (aneuploid) tumours grown in female nude mice. The σ2receptor P:Q ratio of the 66 tumours was 10.6 compared to the σ2receptor P:Q ratio of 9.5 measured for the 66 tissue culture model. The σ2receptor P:Q ratio of the 67 tumours was 4.5 compared to the σ2receptor P:Q ratio of ≈ 8 measured for the 67 tissue culture model. The agreement between the solid tumour and tissue culture data indicates that: (1) the expression of σ2receptors may be a reliable biomarker of the proliferative status of solid tumours and (2) radioligands with both high affinity and high selectivity for σ2receptors may have the potential to non-invasively assess the proliferative status of human solid tumours using imaging techniques such as positron emission tomography or single-photon emission computerized tomography. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Al-Nabulsi I, Mach RH, Wang L-M, Wallen CA, Keng PC, Sten K, Childers SR and Wheeler KT (1999) Effect of ploidy, recruitment, environmental factors, and tamoxifen on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 81: 925–933
Amano S, Inoue T, Tomiyoshi K, Ando T and Endo K (1998) In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer. J Nucl Med 39: 1424–1427
Begg AC (1995) The clinical status of Tpotas a predictor? Or why no tempest in the Tpot!. Int J Radiat Oncol Biol Phys 32: 1539–1541
Begg AC, Hofland I, Van Glabbeke M and Horiot JC (1992) Predictive value of potential doubling time for radiotherapy of head and neck tumor patients. Results from the EORTC cooperative trial 22851. Semin Rad Oncol 1: 22–25
Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE and Coscia CJ (1991) Overexpression of σ receptors in nonneural human tumors. Cancer Res 51: 6558–6562
Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254
Corro R, Giaretti W, Sanguinet G, Geido E, Orechia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M and Vitale V (1995) In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 13: 1843–1850
Dong H, Bertler C, Schneider E and Ritter MA (1997) Assessment of cell proliferation by AgNOR scores and Ki-67 labeling indices and a comparison with potential doubling times. Cytometry 28: 280–288
Dressler LG (1993) DNA flow cytometry measurements and their clinical relevance in node-negative breast cancer patients. Recent Results Cancer Res 127: 61–69
Ehmann UK and Wheeler KT (1979) Cinemicrographic determination of progression and division abnormalities after treatment with 1,3 bis(2-chloroethyl)-1-nitrosourea. Eur J Cancer 15: 461–473
Ehmann UK, Nagasawa H, Petersen DF and Lett JT (1974) Symptoms of X-ray damage to radiosensitive mouse leukemic cells: asynchronous populations. Radiat Res 60: 453–472
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH and Broder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14: 831–838
Haberkorn U, Strauss JG, Reisser CH, Haag D, Dimitrakopoulou A, Ziegler S, Oberdorfer F, Rudat VA and Van Kaick G (1991) Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 32: 1548–1555
Hanner M, Moebius FF, Flandorfer A, Knaus H-G, Striessnig J, Kempner E and Glossman H (1996) Purification, molecular cloning and expression of the mammalian sigma1binding site. Proc Natl Acad Sci USA 93: 8072–8077
Haustermans K, Hofland I, Pottie G, Ramakers M and Begg AC (1995) Can measurements of potential doubling time (Tpot) be compared between laboratories? A quality control study. Cytometry 19: 154–163
Hayes DF (1996) Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res 140: 101–113
Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T and Merkel D (1993) Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482–485
Hellwell SB, Bruce A, Feinstein G, Orringer J, Williams W and Bowen WD (1994) Rat liver and kidney contain high densities of σ1and σ2receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol Mol Pharmacol Sec 268: 9–18
Höchel M, Schlenger K, Knoop C and Vaupel P (1991) Oxygenation of carcinomas of the uterine cervix: Evaluation of computerized O2tension measurements. Cancer Res 51: 6098–6102
Kaufman M (1996) Review of known prognostic variables. Recent Results Cancer Res 140: 77–87
Kekuda R, Prasad P, Fei Y-J, Leibach FH and Ganapathy V (1996) Cloning and functional expression of the human type one sigma receptor (hSigma R1). Biochem Biophys Res Commun 223: 553–558
Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U and Joensuu H (1991) Uptake of11C-methionine in breast cancer studied by PET. An association with the size of the S-phase fraction. Br J Cancer 64: 1121–1124
Liu A, Dence CS, Welch MJ and Katzenellenbogen JA (1992) Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 33: 724–734
Mach RH, Smith CR, Al-Nabulsi I, Whirrett BA, Childers SR and Wheeler KT (1997) σ2receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57: 156–161
Martiat PH, Ferrant A, Labar D, Cogneau M, Bol A, Michael C, Michaux JL and Sokal G (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkins lymphoma using positron emission tomography. J Nucl Med 29: 1633–1637
Minn H and Soini I (1989) [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 15: 61–66
Minn J, Joensuu H, Ahonen A and Klemi P (1988) Fluorodeoxyglucose imaging: a method to assess proliferative activity of human cancer in vivo. Cancer 61: 1776–1781
Miyazawa H, Arai T, Iio M and Hara T (1993) PET imaging of non-small cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med 43: 1886–1891
Moebius FF, Stiessnig J and Glossman H (1997) The mysteries of the sigma receptors: new family members reveal a role in cholesterol synthesis. TIPS 18: 67–70
Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A and Arimizu N (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325–329
Schabel FM (1969) The use of tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res 29: 2384–2389
Seth P, Leibach FH and Ganapathy V (1997) Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun 241: 535–540
Seth P, Fei Y-J, Li HW, Huang W, Leibach FH and Ganapathy V (1998) Cloning and functional characterization of a σ receptor from rat brain. J Neurochem 70: 922–931
Siemann DW, Lord EM, Keng PC and Wheeler KT (1984) Cell subpopulations dispersed from solid tumors and separated by centrifugal elutriation. Br J Cancer 44: 100–108
Takeda N, Diksic M and Yamamoto YL (1996) The sequencial changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. Cancer 77: 1167–1179
Thames HD, Peters LJ, Withers HR and Fletcher GH (1983) Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys 9: 127–138
Tsang RW, Fyles AW, Kirkbride P, Levin W, Manchul LA, Milosevic MF, Rawlings GA, Banerjee D, Pinitilie M and Wilson GD (1995) Proliferation measurements with flow cytometry Tpotin cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results. Int J Radiat Oncol Biol Phys 32: 1319–1329
Vilner BJ and Bowen WD (1992) Characterization of sigma-like binding properties of NB41A3, S-20Y, and N1E-115 neuroblastoma, C6 glioma, and NG108–15 neuroblastoma-glioma hybrid cells. Further evidence for sigma receptorsIn: Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection, Kamenka JM, Domino EF (eds) pp 341–353, NPP Books: Ann Arbor
Vilner BJ, John CS and Bowen WD (1995) Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55: 408–413
Walker JM, Bowen WD, Walker FO, Matsumoto RE, De Costa B and Rice KR (1990) Sigma receptors: biology and function. Pharmacol Rev 42: 355–402
Wallen CA, Higashikubo R and Dethlefsen LA (1984 a) Murine mammary tumor cells in vitro. I. The development of a quiescent state. Cell Tissue Kinet 17: 65–77
Wallen CA, Higashikubo R and Dethlefsen LA (1984 b) Murine mammary tumor cells in vitro. II. Recruitment of quiescent cells. Cell Tissue Kinet 17: 79–89
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wheeler, K., Wang, LM., Wallen, C. et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82, 1223–1232 (2000). https://doi.org/10.1054/bjoc.1999.1067
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1067